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Abstract
Background: Hepatitis C virus (HCV) is estimated to affect 130–180 million people worldwide. Although its origin is
unknown, patterns of viral diversity suggest that HCV genotype 1 probably originated from West Africa. Previous attempts
to estimate the spatiotemporal parameters of the virus, both globally and regionally, have suggested that epidemic HCV
transmission began in 1900 and grew steadily until the late 1980s. However, epidemiological data suggest that the
expansion of HCV may have occurred after the Second World War. The aim of our study was to elucidate the timescale and
route of the global spread of HCV.
Methods and Findings: We show that the rarely sequenced HCV region (E2P7NS2) is more informative for molecular
epidemiology studies than the more commonly used NS5B region. We applied phylodynamic methods to a substantial set
of new E2P7NS2 and NS5B sequences, together with all available global HCV sequences with information in both of these
genomic regions, in order to estimate the timescale and nature of the global expansion of the most prevalent HCV
subtypes, 1a and 1b. We showed that transmission of subtypes 1a and 1b ‘‘exploded’’ between 1940 and 1980, with the
spread of 1b preceding that of 1a by at least 16 y (95% confidence interval 15–17). Phylogeographic analysis of all available
NS5B sequences suggests that HCV subtypes 1a and 1b disseminated from the developed world to the developing
countries.
Conclusions: The evolutionary rate of HCV appears faster than previously suggested. The global spread of HCV coincided
with the widespread use of transfused blood and blood products and with the expansion of intravenous drug use but
slowed prior to the wide implementation of anti-HCV screening. Differences in the transmission routes associated with
subtypes 1a and 1b provide an explanation of the relatively earlier expansion of 1b. Our data show that the most plausible
route of the HCV dispersal was from developed countries to the developing world.
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The World Health Organization (WHO) estimates that 3% of
the world’s population is infected by hepatitis C virus (HCV) [1].
HCV is primarily classified into six genotypes and many subtypes
and, although its origin is unknown, patterns of viral diversity
suggest an origin in either West Africa or Southeast Asia [2–4].
Even though the global HCV epidemic was widespread by 1980, it
was not until 1989 that the virus was identified as the leading cause
of non-A non-B hepatitis [5]. No animal source has been identified
to support a hypothesis of zoonotic transmission [4].
The virus is transmitted by iatrogenic procedures and
intravenous drug use (IDU) [1,6–8]. Notably, several genotypes
and subtypes have been associated with particular parenteral
routes of transmission, for example 1b and 2 with transfusions, 1a
and 3a with IDU [1], and 4a with unsafe injections in Egypt [9].
Infections with genotypes 1 and 4 are less responsive to interferon-
based therapies than those with genotypes 2 and 3 [10–12].
Evolutionary (phylodynamic) analyses have been used success-
fully to infer aspects of the epidemic and transmission history of
viruses such as dengue [13], HIV-1 [14–16], and influenza A [17].
This framework relies on the relationship between nucleotide
sequence evolution and time, and has the ability to provide
estimates of the infected population structure in the past [18].
Phylogeographic methods, which incorporate spatial information,
have also been used to reconstruct the geographic dispersal of
viruses such as HIV-1, HCV, and influenza A (G5N1) [19–21]
and are capable of describing the most plausible scenario of
geographic expansion [22].
Previous attempts to estimate spatiotemporal dynamics of the
global and regional spread of the HCV have suggested that
epidemic transmission of HCV began around 1900 and expanded
steadily until the late 1980s [20,23–25]. However, the outcomes of
these theoretical studies contrast with epidemiological evidence
that the spread of HCV coincided with the massive increase of
iatrogenic procedures and IDU around or after the mid-20th
century [6].
In this study we aimed to elucidate the timescale and route of
the global spread of HCV subtypes 1a and 1b by applying
phylodynamic and phylogeographic methods.
Methods
Study Design
We first used a model dataset to identify and select the most
phylogenetically informative HCV genome regions. Subsequently,
we collated globally representative samples from the selected
genome regions and applied an evolutionary analysis framework to
infer the worldwide spatiotemporal dynamics of the HCV
pandemic.
The Model Dataset
A temporally stratified random sample (n=97) of all available
HCV 1a (n=24), 1b (n=27), 3a (n=24), and 4a (n=22) samples
was selected from the serum bank of the Department of Hygiene,
Epidemiology and Medical Statistics, Athens University Medical
School (model dataset). These samples were obtained from
different anonymized HCV-infected patients and collected during
a 12-y period (1994–2006). One sample was selected per 6-mo
period; when no sample was available in a specific 6-mo interval,
the closest sample to that period was selected. In addition to the
sampling date, the following information was recorded for each
sample: patient’s age, sex, ethnicity, transmission group, and
treatment history. Samples were excluded if patients had a history
of antiviral therapy and/or HIV co-infection, since these factors
can affect the intrahost evolution of the virus [26]. Study approval
was granted by the Institutional Review Board of Athens
University Medical School. Epidemiological risk group informa-
tion is summarised in Table S1.
Selection of Genomic Region
We constructed intergenotype similarity plots by means of the
Simplot program [27] using a window of 500 nt, which was
moved along the HCV genome in steps of 50 nt (Figure 1). These
plots show that E2P7NS2 is the most divergent large (.450 nt)
subgenomic region, followed by the 59 end of NS5B. We therefore
focused on sequencing regions E2P7NS2 and NS5B, thus enabling
us to directly compare their molecular evolution, in the context of
the molecular-clock assumption. We designed genotype-free
primers for NS5B spanning nucleotides 8200–8800 (HCV-H
reference strain numbering) and genotype-specific primers for
E2P7NS2 spanning nucleotides 2540–3290. Sequencing was
performed according to the manufacturer’s instructions (3100
Avant Genetic Analyzer, Applied Biosystems). Primer sequences
are listed in Table S2 and reverse transcription-PCR protocols are
available upon request.
The Global Dataset
In order to apply the optimized framework on a global scale, we
retrieved all the available sequences for these two regions with
known sampling dates up to September 2007 from the Los Alamos
HCV sequence database (http://www.hcv.lanl.gov). Thus, we
downloaded 87 and 86 sequences of NS5B and E2P7NS2,
respectively, for genotype 1a, and 85 sequences of both NS5B and
E2P7NS2 for genotype 1b (global dataset) (Table S3) [28,29]. The
sampling dates ranged from 1977 to 2007 for genotype 1a and
from 1989 to 2006 for genotype 1b. The sampling locations were
United States (n=73), Switzerland (n=11), and Germany (n=3)
for genotype 1a, and United States (n=61), Switzerland (n=22),
Germany (n=2), and Russia (n=1) for genotype 1b. We also used
the newly amplified subtype 1a and 1b Greek sequences. For
genotypes 3a and 4a the availability of sequences with known
sampling dates was insufficient (,10) to attempt a phylodynamic
analysis.
Power Optimization
We performed the analysis several times in order to find the
most statistically powerful way to analyse our data: (i) each region
(NS5B, E2P7NS2) was analysed separately; (ii) both regions were
combined (concatenated) using strains for which sequences were
available in both regions; (iii) the temporal information from both
regions was combined, by applying the estimated E2P7NS2 time
to most recent common ancestor (tMRCA) value as prior on the
NS5B TMRCA for strains available in both regions. In the second
case, we computed a combined likelihood as the product of partial
likelihoods for each region. Each partial likelihood was computed
using a distinct alignment and substitution model (GTR+gamma),
but both partial likelihoods used the same tree (topology and
scaled branch lengths).
Demographic and Molecular Clock Model Selection
In order to select the best-fitting molecular clock and
demographic model, we calculated the marginal likelihoods of
the data conditional on all the evolutionary and demographic
model parameters. We analysed all possible combinations of the
relaxed [30] and strict molecular clock models and of the Bayesian
skyline [18], constant, exponential, and logistic growth coalescent
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sufficient chain mixing (effective sample size .100) before 30610
6
generations and after manual tuning of the sampler. As a result we
estimated a Bayes Factors (BF) for each pair of models, as
implemented in Tracer v1.4 and suggested previously [31].
Phylogenetics and Phylodynamics
HCV genotype and subtype reference sequences were chosen as
follows: Genotype 1 (1a: AF009606, AF387806, AF290978; 1b:
D50483, AB049093, D85516); Genotype 2 (2a: AF169005,
AB047645, D00944; 2b: AB030907; 2c: D50409); Genotype 3
(3a: D28917, D17763; 3b: D49374; 3k: D63821); Genotype 4
(Y11604); Genotype 5 (AF064490, Y13184); Genotype 6 (6a:
Y12083; 6b: D84262; 6d:D84263; 6k: D84264; 6h: D84265; 6g:
D63822).
Sequence alignment was performed using Clustal-W [32] and
subsequently checked manually. We used ModelTest [33] to select
the simplest evolutionary model that adequately fits the sequence
data. Using PAUP [34], we estimated very large trees (.400 taxa)
using Neighbor-Joining (under the Kimura 2-parameter substitu-
tion model) in order to determine the phylogenetic distribution of
the included samples within the global epidemic. We estimated
smaller trees using the program Tree-Puzzle [35] (under the
Tamura-Nei substitution model [36]; rate heterogeneity among
sites was modelled using a discrete gamma distribution with four
rate categories). We used MEGA version 4 [37] to visualize and
decorate the constructed trees. We used root-to-tip regression (as
implemented in the program Path-o-gen; http://tree.bio.ed.ac.uk;
[38]) as an exploratory tool to evaluate the clock-likeness of the
sequenced regions.
We performed phylodynamic analysis using the framework
implemented in BEAST [39]. Markov Chains Monte Carlo
(MCMC) sampling was performed for at least 1610
7 generations,
sampling a tree every 1000 generations. We used the General
Time Reversible model of nucleotide substitution, with rate
heterogeneity among sites modelled using a discrete gamma
distribution with four rate categories. The program Tracer
(http://tree.bio.ed.ac.uk) was used to check for convergence and
to determine whether appropriate mixing of the posterior target
distribution had been achieved (effective sample size .100).
We fitted a shifted bivariate gamma distribution to the posterior
distribution of each tMRCA parameter. This was achieved by
maximum likelihood using the gammafit function implemented
in STATA 8.0 [40]. We calculated the shift of the gamma
distribution as being equal to the modulus of the minimal value of
the estimated tMRCA distribution.
Phylogeography
To track the historical spread of HCV 1a and 1b epidemics, we
reconstructed viral dispersal by applying Slatkin and Maddison’s
phylogenetic method for inferring migratory events [41] to all
available 1a and 1b NS5B sequences by means of the Mesquite
program [42]. This method has previously been used to estimate
viral dispersal of the influenza A (H5N1), HIV, and HCV
epidemics [19–21]. Because our sample is not representative of the
country-specific epidemics, we are not interested here in the
quantitative features of the phylogeographic analysis (migration
matrix). Instead, we intend to simply describe qualitative aspects of
the phylogeography such as the degree of geographic dispersal and
the most plausible origin of the current sample. This approach was
Figure 1. Similarity plot of the genotype 3 full-length reference sequence versus reference sequences for other genotypes along
with the HCV genome. Similar plots are produced for all the genotypes. The shaded regions, E2P7NS2 and NS5B, are clearly the most divergent
ones, and were selected for PCR-sequencing.
doi:10.1371/journal.pmed.1000198.g001
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origin of the HCV 1a and 1b subepidemics in different countries,
owing to the absence of a monophyletic country-specific outlier.
Both HCV 1a and 1b trees were rooted using the other subtype,
i.e., to root subtype 1a we used all the available subtype 1b strains
and vice versa. The phylogeographic analysis was performed
independently for each subtype without taking into account the
outgroup.
For this analysis we classified as developed countries: Australia,
Belgium, Canada, France, Germany, Great Britain, Greece,
Ireland, Japan, Spain, Switzerland, and the United States. We
classified as developing countries: Argentina, Brazil, Cameroon,
China, Egypt, India, Iran, Korea, Martinique, Mongolia, Nepal,
Peru, Philippines, Russia, Singapore, Taiwan, Thailand, Tunisia,
Turkey, Uzbekistan, and Vietnam
Accession Numbers
Subtype 1a and 1b sequence accession numbers from the model
dataset have been deposited in GenBank (http://www.ncbi.nlm.
nih.gov/Genbank) with the following accession numbers:
FJ538017–FJ538098
Results
The Model Dataset
In order to obtain the best molecular clock signal we amplified
and sequenced two specific regions of HCV 1a, 1b, 3a, and 4a, the
NS5B (nt 8200–8800 [nucleotide position in relation with the
HCV-H reference strain]) and the E2P7NS2 (nt 2540–3290)
regions (see Figure 1). For the model dataset comparison of the
NS5B and E2P7NS2 regions shows that E2P7NS2 outperforms
the NS5B in terms of evolutionary linearity or ‘‘clocklike-ness.’’
This finding is apparent in regressions of genetic distance against
sampling time (Figure S1) and in the results of relaxed molecular
clock analyses (Table 1). Thus a strict clock model adequately fits
E2P7NS2, whereas NS5B should be modelled by a relaxed-clock
model (Table 1) [30,43]. The coalescent population parameters
were similar for both regions, suggesting that NS5B retains
substantial information about the shape of genealogy of the strains
(unpublished data). The E2P7NS2 region also outperforms NS5B
in terms of the precision of tMRCA, showing that the co-
estimation of evolutionary rates and the tMRCA in a single step is
feasible (here, ‘‘precision’’ is used in its statistical sense, i.e., the
inverse of the estimation variance). In addition, using the time-
scale estimated from E2P7NS2 as a prior during the analysis of
NS5B resulted in more precise estimates of the tMRCA and
population dynamics (data available on request). These results
suggest that E2P7NS2 offers a significant improvement for
estimating the epidemic history of HCV subtypes.
The Global Dataset
To determine whether the global datasets used in the
phylodynamic analysis were representative of the global HCV
epidemic, we downloaded all available 1a and 1b sequences for a
smaller part of NS5B (nucleotides 8297–8597), for which a much
greater number of sequences was available (992 sequences from 21
countries for subtype 1a; 1,208 sequences from 29 countries for
subtype 1b; details in Table S4). The same dataset (alignment
available upon request) was used in the phylogeographic analysis
(see below). The phylogenetic trees estimated from the smaller
NS5B (nt 8297–8597) region indicate that the global dataset is
representative of the global epidemic (Figure 2). Thus the tMRCA
of the global dataset sequences is a fair approximation of the
tMRCA of the global epidemic, allowing the results from a sample
to be projected and generalized to the global epidemic as a whole,
as has been reported previously for HIV [14]. A detailed
investigation into random sampling of the dated sample from the
globally available sequences is presented in the first part of Text S1.
We performed a phylodynamic analysis using the program
BEAST [39]. In order to select the best fitting model we
investigated parametric and nonparametric models for population
growth [18] and strict and relaxed-clock models [30] of molecular
evolution. We found that in each case (subtype 1a or 1b, region
E2P7NS2 or NS5B) the best fitting model was the relaxed
molecular clock model plus the Bayesian skyline demographic
model (Tables 2, S5, and S6). Interestingly, for subtype 1a the
evidence against a strict clock in the E2P7NS2 region was weak,
indicating that this region is more consistent with a strict clock
than NS5B. As a result we chose the best fitting Bayesian skyline
and relaxed-clock models and thus made no parametric
assumptions about demographic history. We also found that the
precision of tMRCA was maximized (Tables 2 and S7) when the
estimated tMRCA of the E2P7NS2 region was used as a prior on
the tMRCA of the less informative NS5B region.
Evolutionary Rates
Interestingly, previously reported estimates of the substitution
rate for HCV NS5B (5610
24 substitutions/site/year) were close to
the lower bound of our NS5B rate credibility interval (Table 2).
When the E2P7NS2 tMRCA was used as a prior on the NS5B
tMRCA, the estimated rate for NS5B (1–1.9610
23 substitutions/
site/year) is about 2–4 times faster than previously estimated
[25,44]. However, previous analyses used a smaller part of NS5B,
making it difficult to compare estimated rates. In order to directly
compare these estimates we truncated our subtype 1b NS5B
alignment to match the region used in the previous studies [44]
and repeated the analysis (previous estimates of comparable
subtype 1a rates were not available). We estimated the rate of this
truncated region to be 2.5610
23 substitution/site/year (95%
highest posterior density 1.5–3.7610
23), which again is faster than
previously estimated.
The Temporal Spread of HCV 1a and 1b
The Bayesian skyline plot summarizes the spread and epidemic
growth of the globally prevalent HCV genotypes 1a and 1b
(Figure 3). It clearly shows that subtype 1a was in a steady
nonexpanding phase maximum from around 1906 (the lower 95%
credible interval of the tMRCA) to the 1960s, after which it
expanded explosively until around 1980. The subtype 1b epidemic
was in a steady nonexpanding phase maximum from 1922 (the
lower 95% credible interval of the tMRCA) to the late 1940s.
Table 1. Comparison of estimated coefficient of variation
parameter for each subtype and genome region.
Subtype E2P7NS2 NS5B
Subtype 1a 0.092 (0.00002–0.274) 0.31 (0.02–0.56)
Subtype 1b 0.108 (0.00004–0.233) 0.26 (0.02–0.44)
Subtype 3a 0.14 (0.00005–0.334) 0.44 (0.07–0.74)
Subtype 4a 0.117 (0.00007–0.36) 0.48 (0.15–0.84)
Under a relaxed molecular clock, this value represents the clocklike-ness of
sequence evolution (lower values represent less among-branch variation in
evolutionary rate). The 95% highest posterior density (HPD) intervals of each
estimate are given in parentheses.
doi:10.1371/journal.pmed.1000198.t001
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sequences (tips without circles).
doi:10.1371/journal.pmed.1000198.g002
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Similar results were obtained when we excluded the newly
amplified and sequenced 1a and 1b Greek strains from the analysis
(data available upon request). The spread of subtype 1b preceded
that of subtype 1a by approximately 16 y (95% confidence interval
[CI] 15–17) (Text S1).
HCV 1a and 1b Phylogeography
Generally, the hierarchy presented in both phylogeographic
trees (subtype 1a and 1b) (Figure 4) suggests that the earliest
divergence events occurred in developed countries, whilst spread
to developing countries tends to be limited to the most recent
terminal parts of the tree. In order to further investigate the most
plausible source of the global 1a and 1b epidemic we constructed
nonclock phylogenetic trees and annotated them with country-
specific monophyletic clusters and estimates of cluster dates of
origin (where available; see Figure S2). Both trees indicate that
strains from developed countries are dispersed across the whole
tree either as independent lineages or as outliers within cluster of
strains from developing countries; this dispersion is estimated to
have occurred in a period of 10 y for both subtypes (Figures S2
and S3).
Discussion
Our analysis aimed to estimate the spatiotemporal spread of the
global epidemic HCV subtypes 1a and 1b. First, we were able to
improve significantly the analytical framework of HCV phylody-
namics by demonstrating that E2P7NS2 is evolving in a more
clocklike manner than NS5B. Moreover, we showed that HCV is
evolving faster than previously thought and we were able to
provide more precise estimates of the timescale and dynamics of
epidemic growth for subtypes 1a and 1b. These estimates support
a massive expansion of the epidemics between 1940 and 1980, as
opposed to the previous conjecture of a more continual and steady
increase across the whole of the 20th century.
This time frame suggests that the global epidemic of both
subtypes was possibly initiated and sustained by the vast increase
of parenteral iatrogenic procedures during and after World War II
(transfusions, plasma pooling, and unsafe therapeutic injections)
[43–45]. Blood and freeze-dried (lyophilized) pooled plasma could
have served as a vehicle for global HCV dissemination, for the
following reasons: (i) pooling of plasma increased the possibility of
containing and transmitting the virus; (ii) freeze-dried plasma
could be stored easily for a long period and used far from the
blood donation site; (iii) the dry plasma remains infectious; and (iv)
there is ample historical evidence for the shipment of plasma and
stored red cells around the world [45]. The high frequency of
subclinical primary HCV infection and nonspecific symptoms of
other cases might have permitted such an outbreak to escape
attention.
The observed epidemic growth also coincides with the history of
illicit IDU; the US and Canada have the longest history of IDU,
which developed in the late 1920s and spread in the 1930s [46].
Before the Second World War about 40% of addicts seeking
treatment were injecting, and this figure had risen to 70%–90% by
1950 [46,47]. A peak of heroin use in North America occurred at
end of the 1960s [48]; injecting heroin was especially common in
military servicemen, veterans [49], and inner city populations [48].
In Europe and Australia the spread of IDU began in the late 1960s
[46]. In Asia the first important IDU epidemic (amphetamine use)
was in Japan between 1946 and 1956, while in Hong Kong heroin
injecting has been documented since the 1950s [46]. Interestingly,
IDU is relatively recent in many Asian countries such as China,
India, Lao People’s Democratic Republic, Myanmar, Nepal, Sri
Lanka, and Vietnam [46].
The expansion of HCV subtype 1b preceded that of subtype 1a
by at least 16 y (95% CI 15–17), and it probably coincides with the
vast increase in transfusions and unsafe therapeutic injections,
whereas the expansion of HCV 1a is more strongly associated with
the increase in IDU after 1960. Our analysis suggests that the
exponential expansion of HCV 1a and 1b reached a plateau in the
1980s, possibly prior to implementation of anti-HCV screening at
the beginning of the 1990s. These results are consistent with
epidemiological data indicating that the incidence of acute non-A,
non-B hepatitis, and HCV infection greatly increased from the
1960s to the early 1980s and declined before 1990 in the US, Italy,
France, and Greece [50–54]. This decline was probably due to
increased awareness of the medical community to parenteral risks,
better blood donor selection, HBsAg, ALT, anti-HBc, anti-HIV
screening, and the use of viral inactivation of clotting factor
concentrates [55].
Our findings are also corroborated by: (i) HCV data from US
military recruits, which indicate that all genotyped samples
collected during 1948–1955 were found to be subtype 1b [56],
(ii) by modelling data on the incidence of HCV infection in the US
haemophilia population, which is mainly infected with HCV 1a
[57], and (iii) by demography of local epidemics where HCV 1b
infected individuals are systematically older than HCV 1a infected
ones [2,58]. Moreover, the rise in subtypes 1a and 1b also
coincided with the rise of syringe availability [6] and the trends of
IDU in the US [48] and globally [46].
Table 2. Estimated timescale of the global dataset using a relaxed-clock model.
Genomic Region Date of MRCA Rate (10
23 substitution/site/y) CoV
Subtype 1a
E2-P7-NS2 1914 (1818–1956) 1.3 (0.055–2,1) 0.20
NS5B 1900 (1802–1957) 1.0 (0.7–1.4) 0.25
NS5B with E2-P7-NS2 prior 1931 (1906–1957) 1.0 (0.72–1.4) 0.25
Subtype 1b
E2-P7-NS2 1944 (1905–1965) 2.1 (1.1–3.0) 0.230
NS5B 1911 (1806–1959) 1.2 (0.42–2.0) 0.32
NS5B with E2-P7-NS2 prior 1940 (1922–1963) 1.9 (1.2–2.6) 0.32
The 95% highest posterior density (HPD) intervals of each parameter are given in parentheses. CoV, coefficient of variation.
doi:10.1371/journal.pmed.1000198.t002
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and 1b most probably expanded from the developed countries to
the developing world. However, our approach is not immune from
sampling bias since many countries have been under-represented
and a few over-represented (e.g., 399 1a sequences and 89 1b
sequences from the US, 129 1b sequences from China, 276 1b
sequences from Japan, and 276 1b sequences from Spain; Table
S4); in addition most of the sequences do not have sampling date
information. As a result we were not able to perform a full
quantitative analysis of the rates and modes of HCV transmission
Figure 3. Global population dynamics of the hepatitis C virus genotypes 1a and 1b based on relaxed-clock analysis of NS5B. The
tMRCA estimated from E2P7NS2 was used to provide a gamma-distributed prior for the tMRCA of strains also available for NS5B.
doi:10.1371/journal.pmed.1000198.g003
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PLoS Medicine | www.plosmedicine.org 7 December 2009 | Volume 6 | Issue 12 | e1000198Figure 4. Phylogeographic trees of all the partial NS5B sequences available for 1a and 1b subtypes. The red, green, and black lines
indicate events attributed to the sequences sampled from the US, other developed, and developing countries, respectively.
doi:10.1371/journal.pmed.1000198.g004
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aspects of the phylogeographic tree (such as geographic dispersal
and origin), which are likely to be more robust to sampling bias.
The observed phylogeographic patterns of both subtypes are
similar and can be described as a source-sink pattern, with
developed countries representing the source of the spatial spread of
the epidemic [22]. These descriptive patterns of the estimated
phylogeography suggest that the first wave of transmission
(probably from plasma and blood transfusions) facilitated the
spread of HCV initially to developed countries and subsequently
to the developing world where local epidemics were further
established from location specific iatrogenic procedures and IDU
[46].
Interestingly, subtype 1b has been found to be predominant in
all countries with a high prevalence of hepatocellular carcinoma
(HCC), including Japan, Italy, and Spain [59]. Since our analysis
suggests that 1b preceded the 1a epidemic by ,16 y, this
association can be explained by the epidemic being older in these
countries. This finding is reinforced by the observation that the
prevalence of subtype 1b infection in HCC patients is higher than
that of subtype 1a [60,61]; although a higher oncogenic activity of
1b cannot yet be entirely excluded, one other plausible
explanation is that 1b infections are older and thus more likely
to develop severe liver disease. If this is the case then our analysis
predicts that the seroepidemiology of HCV in liver disease patients
will eventually change and that the relative incidence of 1a HCC
cases will increase.
This analysis provides a framework for applying established
phylodynamic methods to the estimation of HCV epidemic
spread, by using the NS5B and E2P7NS2 genomic regions, the
latter being only rarely sequenced. Although data suggest that
HCV genotype 1 as whole is endemic in West Africa and thus may
have originated there [2,3], we show that the most prevalent HCV
subtypes 1a and 1b expanded globally after World War II,
probably through widespread availability of blood transfusions and
blood products, invasive medical procedures, use of unsafe
therapeutic injections, and widespread use of IDU.
Supporting Information
Figure S1 Regression of root-to-tip genetic distances against
sampling date for the E2P7NS2 and NS5B regions in the model
dataset (genotype 3a). The root has been chosen as the branch that
maximizes the coefficient of determination (Pearson’s r), under the
assumption of a strict molecular clock.
Found at: doi:10.1371/journal.pmed.1000198.s001 (0.41 MB
TIF)
Figure S2 Phylogenetic trees of all partial NS5B sequences
available for subtypes 1a (also presented as phylogeographic trees
in Figure 2). This figure shows the phylogenetic trees annotated
with dated nodes (median dates, blue numbers) and country-
specific clusters (colored triangles). Each country-specific cluster is
comprised of at least four taxa and contains at least 80% strains
isolated from the specified country. Country codes are: ES (Spain),
TN (Tunisia), US (United States of America), FR (France), GB
(Great Britain), CH (Switzerland), BR (Brazil), PH (Philippines),
TW (Taiwan), IE (Ireland), RU (Russia), IN (India), JP (Japan),
CN (China), MN (Mongolia), VN (Vietnam). Red circles indicate
dispersed strains isolated from the US.
Found at: doi:10.1371/journal.pmed.1000198.s002 (0.40 MB
TIF)
Figure S3 Phylogenetic trees of all partial NS5B sequences
available for subtypes 1b (also presented as phylogeographic trees
in Figure 2). This figure shows the phylogenetic trees annotated
with dated nodes (median dates, blue numbers) and country-
specific clusters (colored triangles). Each country-specific cluster is
comprised of at least four taxa and contains at least 80% strains
isolated from the specified country. Country codes are: ES (Spain),
TN (Tunisia), US (United States of America), FR (France), GB
(Great Britain), CH (Switzerland), BR (Brazil), PH (Philippines),
TW (Taiwan), IE (Ireland), RU (Russia), IN (India), JP (Japan),
CN (China), MN (Mongolia), VN (Vietnam). Red circles indicate
dispersed strains isolated from the US.
Found at: doi:10.1371/journal.pmed.1000198.s003 (0.42 MB
TIF)
Table S1 Epidemiological risk group distribution for each HCV
subtype in the model dataset. Description of primers used in the
experimental phase.
Found at: doi:10.1371/journal.pmed.1000198.s004 (0.03 MB
DOC)
Table S2 Primers used to amplify the sequences forming the
model dataset. For genotypes 1a, 1b, and 4a we have implemented
a semi-nested approach for the E2P7NS2 region.
Found at: doi:10.1371/journal.pmed.1000198.s005 (0.04 MB
DOC)
Table S3 Sequences of the global dataset, together with their
spatiotemporal sampling information.
Found at: doi:10.1371/journal.pmed.1000198.s006 (0.20 MB
DOC)
Table S4 Country distribution of the global dataset.
Found at: doi:10.1371/journal.pmed.1000198.s007 (0.02 MB
PDF)
Table S5 Model selection results for the subtype 1a global
dataset. ln-likelihoods and log10 Bayes factors (BF) for each pair of
models (model 1=row versus model 2=column). A log10 BF.5
(decibans) is substantial evidence and .10 is strong evidence for
the support of model 1 over model 2.
Found at: doi:10.1371/journal.pmed.1000198.s008 (0.05 MB
DOC)
Table S6 Model selection results for the subtype 1b global
dataset. ln-likelihoods and log10 Bayes factors (BF) for each pair of
models (model 1=row versus model 2=column). A log10 BF.5
(decibans) is substantial evidence and .10 is strong evidence for
the support of model 1 over model 2.
Found at: doi:10.1371/journal.pmed.1000198.s009 (0.04 MB
DOC)
Table S7 Comparison of the precision of different data
combinations in estimating the tMRCA in the global dataset
(95% higher posterior probability). It is easily shown that
maximum precision is achieved when E2P7NS2’s estimate of the
tMRCA is applied as a prior on the tMRCA of NS5B.
Found at: doi:10.1371/journal.pmed.1000198.s010 (0.03 MB
DOC)
Text S1 Testing for random sampling and statistics about the
time lag between subtype 1a and 1b epidemics. Analysis of Figures
S1, S2, and S3.
Found at: doi:10.1371/journal.pmed.1000198.s011 (0.04 MB
DOC)
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Background. About 150 million people (3% of the world’s
population) harbor long-term (chronic) infections with the
hepatitis C virus (HCV) and about 3–4 million people become
infected with this virus every year. HCV—a leading cause of
chronic hepatitis (inflammation of the liver)—is spread
through contact with infected blood. Transmission routes
include medical procedures (for example, transfusions with
unscreened blood) and needle-sharing among intravenous
drug users. This second transmission route is the most
common one in developed countries where blood is now
routinely screened before being used in transfusions. HCV
infection can cause a short-lived illness characterized by
tiredness and jaundice (yellow skin and eyes), but most
newly infected people progress to a symptom-free, chronic
infection that can eventually cause liver cirrhosis (scarring)
and liver cancer. HCV infections can be treated with a
combination of two expensive drugs called interferon and
ribavirin, but these drugs are ineffective in many patients.
Why Was This Study Done? Noone knows for sure where
HCV originated although there is some evidence that it
appeared first in West Africa or Southeast Asia. It is also
unclear when the current HCV epidemic began. In this study,
the researchers try to elucidate both the timescale and route
of the global spread of the HCV epidemic by analyzing the
genome sequence of HCV samples collected at different
times and places. HCV is a ribonucleic acid (RNA) virus. That
is, it stores the information it needs to replicate itself—its
genome—as a series of ‘‘ribonucleotides.’’ Like other RNA
viruses, the HCV genome continually accumulates small
changes (mutations) and, over time, HCV has evolved into
several different ‘‘genotypes,’’ each of which has several
distinct subtypes. Furthermore, the viruses within a single
subtype have subtly different genomes. By analyzing this
viral diversity using complex ‘‘phylodynamic’’ and
‘‘phylogeographic’’ methods, scientists can build up a
picture of how HCV has evolved in populations and how it
has spread to reach its current geographical distribution.
What Did the Researchers Do and Find? By examining
the genomes of HCV samples collected between 1994 and
2006 at the Athens University Medical School (Greece), the
researchers first defined a variable region of HCV called
E2P7NS2 that is more informative for phylodynamic studies
than the NS5B region that has been used in previous studies.
They then retrieved the sequences of both regions for
subtype 1a and 1b samples collected over the past 20–30
years in the Los Alamos HCV sequence database; HCV
subtypes 1a and 1b cause 60% of global HCV infections. The
researchers’ phylodynamic analyses of these globally
representative sequences (collected in the USA, Germany,
Switzerland, and Greece) indicate that the transmission of
HCV subtype 1a occurred at a low rate from 1906 until the
1960s, at which time there was an explosive increase in its
transmission rate. Similarly, subtype 1b transmission
occurred at a low rate from 1922 until the late 1940s but
then increased exponentially. From 1980 onwards, the
prevalence of both subtypes stabilized at a high level. The
researchers’ phylogeographic analyses (which considered 1a
and1b NS5B sequences collected in 21 and 29 countries,
respectively) suggest that HCV subtypes 1a and 1b may have
spread from the developed to the developing world.
What Do These Findings Mean? These findings indicate
that the epidemic of HCV subtype 1b began in the 1940s
when the use of transfused blood and blood products
became widespread whereas the start of the subtype 1a
epidemic coincided with the expansion of injected drug use
that occurred in the 1960s. The findings also suggest that the
transmission rates of both subtypes may have slowed before
the widespread implementation of HCV screening in the
early 1990s, possibly because the medical community was
aware by then of the general risks associated with blood
contamination. Finally, these findings provide new insights
into how the HCV epidemic spread around the world and
suggest that HCV may be evolving faster than previously
thought. However, because this study relied on a small
number of samples collected over a short time period, its
findings need to be confirmed in larger studies.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000198.
N The World Health Organization provides detailed informa-
tion about hepatitis C and HCV
N The US Centers for Disease Control and Prevention
provides information on hepatitis C for the public and
for health professionals (information is also available in
Spanish)
N The US National Institute of Diabetes and Digestive and
Kidney Diseases provides basic information on hepatitis C
(in English and Spanish)
N MedlinePlus provides links to further resources on hepatitis
C
N The Los Alamos HCV database is available
N The US National Center for Biotechnology Information
provides a science primer on how scientists reconstruct
evolutionary pathways from sequence information
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